Neurofibroma screening: Difference between revisions
Jump to navigation
Jump to search
(Mahshid) |
Sara Mohsin (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Neurofibroma}} | {{Neurofibroma}} | ||
{{CMG}}; {{AE}} {{SC}} | {{CMG}}; {{AE}}{{S.M.}} {{SC}} | ||
==Overview== | ==Overview== | ||
According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine [[screening]] for neurofibroma. | According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine [[screening]] for neurofibroma. | ||
Revision as of 17:37, 25 March 2019
|
Neurofibroma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Neurofibroma screening On the Web |
|
American Roentgen Ray Society Images of Neurofibroma screening |
|
Risk calculators and risk factors for Neurofibroma screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2] Shanshan Cen, M.D. [3]
Overview
According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine screening for neurofibroma.
Screening
According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine screening for neurofibroma.